NSEAllotment of Securities7 Jul 2026 · 7 Jul 2026, 06:05 pm
Allotment of Securities
Bliss GVS Pharma Limited · BLISSGVS
✦ AI Summary
Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187,750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026, increasing the issued, subscribed & paid-up share capital of the Company.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026
Attachments (1)
📄pdf
Download →
BLISSGVS_07072026180521_Outcome_of_ESOP_Allotment_Committee.pdf
View document text
July 07, 2026
To To
The Manager, Listing Department The General Manager, Listing Department
National Stock Exchange of India Ltd. BSE Limited
Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers,
Bandra-Kurla Complex, Bandra (East), Dalal Street,
Mumbai- 400 051 Mumbai- 400 001
Symbol: BLISSGVS Scrip Code: 506197
Dear Sir/Madam,
Subject: Allotment of Shares under Bliss GVS Pharma Limited – Employee Stock Options
Plan, 2019
We like to inform you that the ESOP Allotment Committee of the Company, at its meeting
held today i.e. July 07, 2026, has approved the allotment of 1,87,750 equity shares of the face
value of Re. 1/- each to the eligible employee who has exercised their stock options under
Bliss GVS Pharma Limited–Employee Stock Option Plan 2019 (‘Bliss GVS ESOP-2019’).
Consequent to the aforesaid allotment, issued, subscribed & paid-up share capital of the
Company has increased as under:
From To
10,60,56,223 equity shares of Re. 1/- each 10,62,43,972 equity shares of Re. 1/- each
aggregating Rs. 10,60,56,223/- aggregating Rs. 10,62,43,972/-
In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity)
Regulations, 2021 the details of shares allotted as above are given in ‘Annexure-I’ to this
intimation.
Kindly take the above information on record.
Thank you.
Yours faithfully,
For Bliss GVS Pharma Limited
Aditi Bhatt
Company Secretary
Encl: As above
‘Annexure – I’
Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity)
Regulations, 2021
Company Name and address of Registered Bliss GVS Pharma Limited
Office Add: 102, Hyde Park, Saki Vihar Road,
Andheri (East), Mumbai - 400072
Name of the Stock Exchanges on which the BSE Limited
Company’s shares are listed The National Stock Exchange of India
Limited
Filing date of the statement referred in 14/02/2020
regulation 10(b) of the SEBI (Share Based
Employee Benefits) Regulations, 2014 read
with the SEBI (Share Based Employee
Benefits and Sweat Equity) Regulations,
2021 with the recognized Stock Exchange
Filing Number, if any Application No:
BSE – 106063
NSE – 23188
In-Principle Approval Letter:
BSE: DCS/FL/DS/ESOP-IP/542/2019-20
dated February 27, 2020
NSE: NSE/LIST/23188 dated March 04,
2020
Title of the Scheme pursuant to which Bliss GVS Pharma Limited–Employee Stock
shares are issued, if any Option Plan, 2019
Kind of security to be listed Equity Shares
Par value of the shares Re. 1/- per share
Date of issue of shares July 07, 2026
Number of shares issued 1,87,750
Share Certificate No., if applicable Not Applicable
Distinctive number of the share, if 10,60,56,223 to 10,62,43,972 (both inclusive)
applicable
ISIN Number of the shares if issued in INE416D01022
Demat
Exercise price per share Rs. 43/- per share
Premium per share Rs. 42/- per share
Total Issued shares after this issue 10,62,43,972
Total Issued share capital after this issue Rs. 10,62,43,972 /-
Details of any lock-in on the shares Lock in for a period of 6 (six) months from
the date of allotment of Equity Shares.
Date of expiry of lock-in January 06, 2027
Whether shares are identical in all respects All equity shares of the Company allotted
to existing shares, if not, when will they pursuant to the exercise of stock options
become identical? shall rank pari passu with the existing equity
shares of the Company
Details of listing fees, if payable Not applicable